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A B S T R A C T
Polyoxometalates (POMs) are promising inorganic inhibitors for P-type ATPases. The experimental models used
to study the effects of POMs on these ATPases are usually in vitro models using vesicles from several membrane
sources. Very recently, some polyoxotungstates, such as the Dawson anion [P2W18O62]6−, were shown to be
potent P-type ATPase inhibitors; being active in vitro as well as in ex-vivo. In the present study we broaden the
spectrum of highly active inhibitors of Na+/K+-ATPase from basal membrane of epithelial skin to the bi-capped
Keggin-type anion phosphotetradecavanadate Cs5.6H3.4PV14O42 (PV14) and we confront the data with activity of
other commonly encountered polyoxovanadates, decavanadate (V10) and monovanadate (V1). The X-ray crystal
structure of PV14 was solved and contains two trans-bicapped α-Keggin anions HxPV14O42(9-x)-. The anion is built
up from the classical Keggin structure [(PO4)@(V12O36)] capped by two [VO] units. PV14 (10 μM) exhibited
higher ex-vivo inhibitory effect on Na+/K+-ATPase (78%) than was observed at the same concentrations of V10
(66%) or V1 (33%). Moreover, PV14 is also a potent in vitro inhibitor of the Ca2+-ATPase activity (IC50 5 μM)
exhibiting stronger inhibition than the previously reported activities for V10 (15 μM) and V1 (80 μM). Putting it
all together, when compared both P-typye ATPases it is suggested that PV14 exibited a high potential to act as an
in vivo inhibitor of the Na+/K+-ATPase associated with chloride secretion.
1. Introduction
Polyoxometalates (POMs) are inorganic anionic metal oxide clusters
exhibiting a broad diversity of structures and outstanding properties
leading to their application in many fields [1–5]. The usage of biolo-
gically active POMs for medical purposes is continuously increasing and
thus attracting more and more attention from scientist coming from
medical- and biology-related research areas [5–8]. P-type ATPases
constitute a large family of ion pumps, which are found in all kingdoms
of life and are responsible for many biologically essential processes
assigning them important roles in health and diseases [9–12]. There-
fore, P-type ATPases represent important pharmacological targets being
reflected by the substantial number of drugs targeting these ion pumps
[11].
Forty years have passed since the discovery that the muscle in-
hibitor factor (MIF) and the Na+/K+-ATPase inhibitor (present in
commercial ATP) contained vanadium in the +V oxidation state (as
vanadate VO43−) [13]. Actually, it is well known that vanadate ions or
vanadium complexes inhibit or stimulate the activity of many enzymes
[14]. In fact, the serendipitous discovery of vanadate as a Na+/K+-
ATPase inhibitor [13] leads us, 40 years after, to the discussion on
POMs as putative drugs in the treatment of several diseases in which the
molecular targets are established to be precisely the ion pumps such as
Na+/K+-ATPase and Ca2+-ATPase [12,14–16]. Furthermore, POMs are
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particularly known as inhibitors of others enzymes such as phospha-
tases, ecto-ATPases or cholinesterases [6–8,14,17–21]. For the majority
of common drugs used in therapy as P-type ATPase inhibitors, the main
target is the Na+/K+-ATPase [11]. These drugs are being investigated
for several disease treatments such as heart failure, antipsychotic, anti-
malaria and also used as anesthetics, tumor promoter, antibiotic and
insulin mimetic agents, and, very importantly, they present inhibitory
capacity not so different from POMs [11,12]. Previously published data
regarding the Ca2+-ATPase inhibition are available for decaniobate
(abbreviated as Nb10) [Nb10O28]6− (IC50= 35 μM) [16] and for
Keggin-based polyoxotungstates (POTs) such as mono-substituted
Keggin structure [TiW11CoO40]8− (4 μM), tri-lacunary [A-α-
SiW9O34]10− (16 μM) and [B-α-AsW9O33]9− (20 μM), lacunary Dawson
type [α-H2P2W12O48]12− (11 μM), and also for [As2W19O67(H2O)]14−
(28 μM) [22].
Herein, we report and compare for the first time the effects of three
polyoxovanadates (POVs), namely phosphotetradecavanadate,
HxPV14O42(9-x)- (abbreviated as PV14), monovanadate HxVO4(3-x)- (V1)
and decavanadate HxV10O28(6-x)- (V10) on the activity of P-type ATPases
using two different experimental models: the in vitro Ca2+-ATPase ac-
tivity of sarcoplasmic reticulum (SR) vesicles and the ex-vivo activity of
Na+/K+-ATPase using a model obtained from basal membrane of
epithelial skin. To our knowledge those represent the first ex-vivo stu-
dies describing the effects of PV14 and V10 in the processes of epithelial
chloride secretion energized by basolateral Na+/K+-ATPase activity.
Furthermore, we also provide full characterization of the PV14 prepared
as Cs5.6H3.4PV14O42 including X-ray crystal structure analysis.
2. Experimental section
2.1. Materials and characterization methods
Vanadium and cesium contents were determined by ICP-MS using
Perkin-Elmer ELAN 6000 instrument. FT-IR spectra were collected on a
Bruker Vertex 70 instrument by ATR method. 51V nuclear magnetic
resonance spectroscopy measurement of 1mM PV14 aqueous solution
(with 10% of D2O, 20 °C) was taken on a Bruker AV II+ 500MHz in-
strument operating at 131.60MHz for 51V nucleus (2500 scans, accu-
mulation time 0.05 s, relaxation delay 0.01 s). Chemical shift values are
given with reference to VOCl3 (0 ppm) as a standard.
The X-ray intensity data were measured on a Bruker X8 Apex2
diffractometer equipped with multilayer monochromators, Mo K/α
(λ=0.71073 Å) INCOATEC micro focus sealed tubes and Oxford
cooling system. The structure was solved by Patterson methods and
refined by full-matrix least-squares techniques. Non‑hydrogen atoms
were refined with anisotropic displacement parameters. The following
software was used: Bruker SAINT software package [23] using a
narrow-frame algorithm for frame integration, SADABS [24] for ab-
sorption correction, OLEX2 [25] for structure solution, refinement,
molecular diagrams and graphical user-interface, Shelxl [26] for re-
finement and graphical user-interface, SHELXS-2016 [27] for structure
solution, SHELXL-2016 [28] for refinement, Platon [29] for symmetry
search and check. The graphic for Fig. 1 was obtained with Diamond
4.5.3 [30].
Common analytical solutions, reagents and materials used for the
preparation of the calcium pump vesicles and for the kinetic studies
described below were prepared from reagents obtained from Sigma-
Aldrich (Portugal, Austria). The stock solutions of monovanadate (V1,
50mM, pH 10.5) and decavanadate (V10, 5 mM, pH 4.0) were prepared
similarly as in our previous studies on V10 interactions with proteins
and in vivo studies [14,16,17]. Briefly, NH4VO3 was dissolved in milliQ
water with heating, the pH was adjusted to 10.5 with NaOH and the
solution was heated until colorless solution was obtained. After cooling,
the solution was splitted into two parts. The pH of one of them was
adjusted to 4.0 with HCl to obtain an orange solution of V10. The other
solution is named monomeric vanadate solution V1.
2.2. Preparation and characterization of phosphotetradecavanadate
The bicapped Keggin–type phosphotetradecavanadate
Cs5.6H3.4PV14O42·12H2O (PV14) was synthesized by modification of
published procedures [31–33]: NaVO3 (4.5 g, 37mmol) was dissolved
in 40mL of hot distilled water. H3PO4 (0.636mL, 9.3mmol) was added
and the pH was adjusted to 2.5 with conc. HNO3. The solution was
heated to 50 °C, CsCl (2 g, 12mmol) was gradually added into it and the
solution was maintained at 50 °C several hours to provide red cubic
crystals of the title compound. Elemental analysis for Cs5.6PV14H27.4O54
(calc.): V 31.2 (31.3), Cs 29.7 (30.0). Stock solutions (1mM aqueous
solution, pH 5.5) of PV14 for inhibition studies were prepared daily
wherever adequate by dissolution of the solid compound in water and
kept on ice during the utilization.
2.3. Ca2+-ATPase (in vitro) and Na+/K+-ATPase (ex-vivo) inhibition
studies
Detailed description of experimental procedures necessary for in-
hibition studies (preparation of sarcoplasmatic reticulum Ca2+-ATPase
vesicles and epithelial short circuit current in Ussing chambers ex-vivo)
can be found in [16,22]. In short: Isolated sarcoplasmic reticulum (SR)
vesicles prepared from rabbit skeletal muscles as described elsewhere
[16] were suspended in 0.1M KCl, 10mM HEPES (pH 7.0), diluted 1:1
with 2.0M sucrose and frozen in liquid nitrogen prior to storage at
−80 °C. The ATPase activity and the inhibition of POVs solutions was
measured taken into consideration the decrease of the OD (Optical
density) per minute in the absence (100% activity) and in the presence
of several PV14 concentrations, according to described elsewhere [16].
All experiments were performed at least in triplicate. The inhibitory
power of the investigated PV14 was evaluated determining IC50 values
meaning the POM concentration inducing 50% of Ca2+-ATPase in-
hibition of the enzyme activity. Aqueous stock solutions of these PV14
were prepared in concentrations up to 1 or 0.5mM stock solution in
water considering a Mr of 2380.01 g/mol. Solutions of PV14 were pre-
pared daily wherever adequate by dissolution of the solid compounds in
water and kept on ice during the utilization to avoid putative POM
decomposition.
For the ex-vivo study killifish (F. heteroclitus, 4–8 g) was collected
with fish traps from the saltmarshes of Ria Formosa (Faro) and main-
tained in Ramalhete Marine Station (CCMar, University of Algarve,
Faro, Portugal). All animal protocols were performed under a “Group
C” license from the Direcção-Geral de Veterinária, Ministério da
Agricultura, do Desenvolvimento Rural e das Pescas, Portugal.
The experimental setup for the ex-vivo study is illustrated in Fig. 1A.
ET50 is the effective time (in minutes) necessary to reach 50% of the
maximum effects for each POM concentration. The maximum in-
hibitory effect (%) of the ATPase activity by the POVs solutions and the
effective time (ET50) necessary to reach 50% of the maximum effects (in
minutes) were measured, taken into consideration the % decrease of
short circuit current (Isc, μA/cm2) in the absence (100% activity) and
upon addition of PV14 (Fig. 1B). In the opercular epithelium of killifish
used for our studies, Isc is a direct measure of apical chloride secretion
mediated by chloride channels, which relies on an intact basolateral
Na+/K+-ATPase to function [34,35]. Methodology for ex-vivo oper-
cular epithelia preparation followed our current methods [22,36]. Fish
were anaesthetized with 2-phenoxyethanol (1:2000 v/v), sacrificed by
decapitation and the cranium was cut longitudinally. The gills and
other tissue remains were removed carefully and the epithelial skin
covering the opercular bone were dissected out and transferred to fresh-
gassed saline (99.7:0.3 O2/CO2) with the following composition (all
values in mM): NaCl, 160; MgSO4, 0.93; NaH2PO4, 3; CaCl2 1.5,
NaHCO3 17.85, KCl 3; Glucose 5.5 HEPES 5; pH 7.8. Measurement of
short circuit current (Isc, μA/cm2) was performed in symmetric con-
ditions under voltage clamp to 0mV. Open circuit potential (Vt, mV)
and Isc were monitored by means of Ag/AgCl electrodes connected to
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the chambers by 3mm bore agar bridges (1M KCl in 3% agar).
Clamping of epithelia to 0mV and recording of Isc was performed by
means of VCC600 voltage clamp amplifiers (Physiologic Instruments,
San Diego, USA). Bioelectrical data was continuously digitized trough a
Lab-Trax-4 (WPI, Sarasota, US) onto a Macbook laptop using Labscribe3
Software (Iworks systems, Dover, US). All experiments were performed
at least in triplicate. Calculations of ET50 and Maximum effect were
performed using GraphPad Prism version 6.00 for Macintosh
(GraphPad Software, La Jolla California USA).
3. Results and discussion
3.1. Characterization of phosphotetradecavanadate
The non-stochiometric composition found for
Cs5.6H3.4PV14O42·12H2O (PV14) is in good agreement with the pre-
viously reported analogical salts K5.72H3.28[PV14O42] [31] and
Rb5.89H3.11[PV14O42] [37]. The characteristic bands in IR spectra re-
present PeO (1053m cm−1) and V]O stretching vibrations (934
vs+862 s cm−1), as well as vibrations of various V–O–V bridges (two
groups of bands at 800, 741, 709 cm−1+ 590, 557, 476, 428 cm−1)
(Fig. S2).
51V NMR spectrum of a 1mM solution of PV14 (Fig. 2) revealed
three characteristic peaks at −592 ppm, −574 ppm, −524 ppm in the
ratio 4:8:2. The chemical shift at −524 ppm corresponds to vanadium
atoms of the two capping V]O units that are pentacoordinated, the
remaining peaks corresponds to octacoordinated vanadium atoms of
the Keggin cage connected to the capping V atoms through oxido
bridges (−574 ppm) or not connected (−592 ppm). Based on published
speciation studies in the ternary H+/H2VO4−/H2PO4− system with
found chemical shifts −589 ppm, −572 ppm, −521 ppm for
H3[PV14O42]6− species and −598 ppm, −580 ppm, −530 ppm for
H4[PV14O42]5− species [38], the NMR shows that the found chemical
shifts lie in the expected region.
The X-ray crystal structure of PV14 (Fig. S1; Table S2 and Table S3)
was solved in P-4n2 space group and the unit cell contains two trans-
bicapped α-Keggin anions HxPV14O42(9-x)- (Fig. 3). The anion is built up
from the classical Keggin structure [(PO4)@(V12O36)] capped by two
[VO] units. The V]O groups are located in surface moieties formed by
four adjacent oxygen atoms at VeO distances in the range
1.838–2.238 Å (Fig. S1). The two [VO] units are in opposition and
occupy three different pairs of positions on the surface of the Keggin
anion with various occupancies giving the overall sum formula as de-
termined by ICP-MS analysis. The high degree of disorder in the area of
counter ions and water molecules forced the use of squeeze. According
to the result of elemental analysis (5.6 Cs), the excluded volume
(1208.2 Å3) and number of electrons (1112.0), the following maximum
content is possible: 12 Cs and up to ~45 H2O molecules. This leads to
~1112 electrons and ~1200 Å3 by the model. This is in very good ac-
cordance to approximately twelve charges of the two POMs in the unit
cell needed. The analogous compounds K5.72H3.28[PV14O42] [32] and
Rb5.89H3.11[PV14O42] [37] also exhibited the same disorder that was
treated similarly.
3.2. Inhibition of Ca2+-ATPase by phosphotetradecavanadate: in vitro
studies
The effect of phosphotetradecavanadate (PV14) on the activity of
sarcoplasmic reticulum Ca2+-ATPase from skeletal muscle (in vitro
Fig. 1. A) Schematic representation of the experi-
mental setup of the opercular epithelium of killifish
used for our ex vivo studies. Isc was measured in
voltage clamp, and in this model represents chloride
secretion. The process is energized by basolateral
Na+/K+-ATPase and chloride is secreted apically
via a chloride channel. B) Original trace of the effect
of short circuit current (Isc, μA/cm2) in the oper-
cular epithelium of killifish mounted in Ussing
chambers and kept under voltage clamp
(Vt=0mV) after PV14 addition. Effective time 50
(ET50), time necessary to reach 50% of the max-
imum effects is shown in minutes; and maximum
inhibitory effects are calculated as the % of basal
values.
Fig. 2. 51V NMR spectrum of 1mM aqueous PV14 solution at autogenous pH
(5.5). Legend: a′, a″, a‴ HxPV14O42(9-x)-; b H3VPO7−.
Fig. 3. Polyhedral representation of the structure of HxPV14O42(9-x)- anion in
PV14 as revealed by X-ray structure analysis. Polyhedron legend: pink {PO4},
blue {VO6}, orange {VO} capping unit.
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model) was investigated. It was observed that PV14 inhibits the Ca2+-
ATPase activity, expressed as a percentage of the control obtained
without inhibitor, in a concentration dependent manner (Fig. 4). The
inhibitory power of PV14 was evaluated using IC50 values (POM con-
centration at which it induces 50% of Ca2+-ATPase inhibition of the
enzyme activity) and the IC50 value of 5.4 ± 0.5 μM was obtained.
Ca2+-ATPase IC50 values of inhibition below 1 μM were previously
determined for polyoxotungstates (POTs) such as [α-P2W18O62]6−
(0.6 μM) and [H10Se2W29O103]14− (0.3 μM), whereas the lowest po-
tency was observed for [TeW6O24]6− (IC50= 200 μM) [22]. It was
previously determined that decavanadate V10 (IC50= 15 μM) is more
potent Ca2+-ATPase inhibitors than V1 (IC50= 80 μM). Herein, we
show that PV14 is the strongest inhibitor of the calcium pump
(IC50= 5 μM) among so far investigated vanadates. For both Nb10 and
V10, it was previously observed that they showed to be Ca2+-ATPase
non-competitive inhibitors regarding the natural ligand Mg-ATP [16].
PV14 presented a mixed type inhibition (Fig. 5), as was previously ob-
served for [α-P2W18O62]6− and [TeW6O24]6− [22] suggesting that it
can interact with the Ca2+-ATPase whether or not the enzyme has al-
ready bound substrate and pointing out to the existence of two distinct
protein binding sites for these types of POMs. Only for V10 a binding site
in the Ca2+-ATPase was previously described, involving at least three
protein domains including the phosphorylation and the nucleotide
binding sites [39]. Studies about the type of inhibition and the me-
chanism of action of the other POMs interactions with P-type ATPases
are to our knowledge still to be determined [16,17,22].
3.3. Inhibition of Na+/K+-ATPase by phosphotetradecavanadate: ex-vivo
studies
As pointed out in Fig. 1, modification of Isc provides an immediate
read-out of inhibitory/stimulatory effects on either the apical chloride
channel, or the basolateral Na+/K+-ATPase induced by PV14. Isc is
measured in voltage clamp, and in this model represents chloride se-
cretion. The process is energized by basolateral Na+/K+-ATPase and
chloride is secreted apically via a chloride channel. In this polarized
epithelium, both mechanisms are required to be intact to sustain the
process of secretion. Therefore, inhibitory effects of POMs on the ba-
solateral side (where Na+/K+-ATPase is located) result in inhibitory
effects on Isc. Herein, it was observed that when PV14 was added to the
basal side (Fig. 1), it does inhibit the Na+/K+-ATPase activity (ex-
pressed as the % of maximum inhibition, in a concentration dependent
manner, Fig. 6A). Thus, for 10 μM a maximum inhibition of 78% of the
basal current was observed whereas a 50% inhibition is obtained for
even less than 1 μM PV14. On the other hand, the addition of PV14 to the
apical side was not accompanied by an effect on Isc, ruling out chloride
channels as putative targets of PV14, at least in a range of concentra-
tions up to 10 μM. From the data of Fig. 6A, we calculated an IC50
values of 1.4 ± 0.1 μM for the ex-vivo Na+/K+-ATPase inhibition. In
addition, it has to be noted that besides the maximum inhibitory effect
(providing information about inhibitor efficacy) also ET50 values
(providing information about inhibition velocity) can be appreciated to
characterize the biological effects of the inhibitor. It was observed that
the value of ET50 decreases from 21 to 7min upon increasing PV14
concentration (Fig. 6B). When comparing different POMs, this negative
correlation does necessary mean that the lowest ET50 value implies a
higher inhibition. In fact, it was observed that decavanadate at the same
concentration (10 μM) exhibits the maximum inhibition of 66% and an
ET50 of 14min; whereas for the monomeric vanadate (at 10 μM) only
33% of maximum inhibition was observed, but a lower ET50 was de-
termined (6min).
A simultaneous comparison of these three vanadate species, PV14,
V10 and V1 at the same concentration of 10 μM (Fig. 7) clearly illus-
trates that PV14 (blue line) is the most potent ex-vivo inhibitor (78%



















Fig. 4. Inhibition of Ca2+-ATPase activity by
PV14. Ca2+-ATPase was measured spectro-
photometrically at 340 nm and 22 °C, using
the coupled enzyme pyruvate kinase/lactate
dehydrogenase assay. The experiments were
initiated after the addition of 10 μg/mL cal-
cium ATPase, in the presence or absence of
4% (w/w) of calcium ionophore A23187.
Data are plotted as means± SD. The results
shown are the average of triplicate experi-
ments.
y = 0.002x + 0.0122  R² = 0.9578





















[PV14] = 0 µM
[PV14] = 5 µM
Fig. 5. Lineweaver-Burk plots of Ca2+-ATPase activity in the absence (blue)
and in the presence (orange) of 5 μM of the polyoxometalate PV14.The plots
were used for determining the type of enzyme inhibition. The POM PV14 pre-
sented a mixed type of inhibition. Data are plotted as means± SD. The results
shown are the average of triplicate experiments.
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after 30min upon addition), whereas for decavanadate (red) and va-
nadate (green) only minor effects were observed. It can be also ob-
served, a constant height of the current deflections used to calculate
tissue resistance implying that the ex-vivo preparation maintained its
integrity and selectivity before and after POM exposure (Fig. 7). For
these studies a positive control experiment was performed with the
conventional Na+/K+-ATPase inhibitor ouabain. Ouabain (at 10 μM)
showed a maximum inhibition value of 100% and an ET50 of 3.2 min
[22]. By inhibiting the basolateral Na+/K+-ATPase activity, ouabain
concomitantly prevents apical chloride secretion. Cs+, in contrast with
rubidium, is known not to affect the activity of this type of enzyme
[40].
Let us briefly comment on the mechanism of P-type ATPases in-
hibition by POMs. POMs clearly exhibit different types of interaction
with different P-type ATPases [12,14]. For example, the orthotungstate
(HWO42−) presents a very low inhibition capacity (IC50= 1.5mM) for
the Na+/K+-ATPase [15], while for another ion pump, SR Ca2+-AT-
Pase is the IC50= 400 μM [16]. Herein, taking into account the Ca2+-
ATPase IC50 values of inhibition for PV14 (IC50= 5 μM) and V10
(IC50= 15 μM) apparently the lower negative charge (−6) for V10, at
physiological pH and according to its pKas values [14,16], in compar-
ison to PV14 (−9) is not favoring enzyme inhibition. Very recently, for
high affinity POTs, exhibiting IC50 values lower than 16 μM, it was
described a correlation between their activity (IC50 value) and their
charge density, as well as by volume of POM anion [22]. Also recently,
a combination of NMR studies, ab initio calculations and crystal-
lographic analysis point out to specific molecular interactions between
H3PW12O40 or H4SiW12O40 and the Na+/K+-ATPase [41]. POMs-pro-
tein interactions observed previously with myosin, actin and calcium
ATPase [12,14,16,17,22,42,43] were described to be mostly of elec-
trostatic nature including hydrogen bonds, but could also involve direct
interaction with cysteins, as described for the P-type ATPase and actin
[17,43]. Thus, besides electrostatic interactions, specific bonding
modes underpinning their relative affinities and site recognition, and
the structure and accessibility of the ATPase site for each crystal-
lographically defined enzyme/pump relative to the inhibitory effec-
tiveness of each POM are still to be determined [44–46]. In conclusion,
the study of protein-POMs interactions is of utmost importance to ex-
plain and improve inhibition of certain enzymes for potential drug
development [47–49].
As referred above, only few studies described POMs as inhibitors of
the hydrolytic activity of several P-type ATPases [15,16]. In these P-
type ATPases studies, normally vesicles from cellular membranes or
organelles are used and constitute in vitro models for the study of POMs
toxicity effects. However, in the majority of these studies, the stability,
as well others factors, of the compounds and/or the putative decom-
position into others species are not taken in consideration. Thus, this
possibility must be considered and several papers were published over
the last years [49–56]. Therefore, if the polyoxometalates species re-
sponsible for the observed effects are not always possible to be de-
termined, participation of other species than the ones initially added to
the biological system should be taken into account [49–57].
In fact, regarding the in vitro studies of POMs for the P-type ATPases
Fig. 6. A) Maximum inhibitory effects are calculated as the % of basal values
and B) Effective time 50 (ET50), time necessary to reach 50% of the maximum
effects (shown in minutes); obtained for 1, 2.5 and 10 μM PV14 concentrations.
Data are plotted as means± SD. The results shown are the average of triplicate
experiments at 22 °C.
Fig. 7. PV14, V10 and V1 inhibition (%) of the Na+/K+-ATPase activity from
basal membrane of the skin epithelia. PV14 (10 μM) inhibited 78% with an ET50
of 6.4min (blue) whereas lower effects were observed for V10 (red) (66% in-
hibition, ET50 13.7) and for V1 (green) (33% and ET50 6.4min). Perpendicular
lines were used to calculate tissue resistance. As it can be observed, the ex vivo
epithelia preparations retained integrity and selectivity after compounds ex-
posure.
G. Fraqueza, et al. Journal of Inorganic Biochemistry 197 (2019) 110700
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[15,16] it is possible to find, for instance, different experimental con-
ditions such as temperature (25 and 37 °C), different times upon in-
cubation depending on the kinetic studies used (2, 15 or 30min) and of
course different concentration range due to different IC50 values of
ATPase activity inhibition. After incubation, both higher temperature
and time would favor the decomposition of the added POM and
therefore the appearance of different species that might also have a
contribution for the observed inhibitory effects.
In this paper, the temperature was maintained for both in vitro and
ex-vivo studies but the time after addition of the PV14 were clearly
different, 1 min for the Ca2+-ATPase assays, and 5 to 10min incubation
for the Na+/K+-ATPase assays. The determination of the inhibitory
capacity needs also different times, 2–3min for the Ca2+-ATPase and
30min for the Na+/K+-ATPase. Moreover, the mediums are different
and also with slight different pH values. Therefore, the experimental
conditions are not always favoring the putative comparison with dif-
ferent experimental conditions and methodologies.
In previous studies with V10 and Ca2+-ATPase and other muscle
proteins (such as myosin and actin) the putative reduction of vanadate
was always taken in consideration [14,43,49]. In fact, reduction of V10
to oxidovanadium(IV) (VO2+), was previously observed upon actin
interaction, but only after 90min incubation and with huge amounts of
protein. Moreover, in the presence of the natural ligand (ATP) the va-
nadate reduction was not observed, suggesting that decavanadate in-
teraction at the actin ATP binding is needed for the reduction of va-
nadate [43,49]. Herein, at the experimental in vitro and in vivo
conditions the redox stability of PV14 during the biological measure-
ments would be hard or impossible to be determined not only because
of the concentrations used, in the order of microM, but also because of
the time upon exposition, that is in the scale of a few minutes. Still, it is
well known that intracellular V(V) can be reduced to oxidovanadium
(IV) [58–61].
Putting it all together, and taking into account the IC50 values de-
termined, the Keggin type polyoxovanadate PV14 exibited a high po-
tential to act as an in vivo inhibitor of the Na+/K+-ATPase than V10 or
V1. However, as referred before for V10 [49], and also due to the va-
nadium complex chemistry and biochemistry we cannot exclude that
besides PV14 the observed effects might be due to other vanadate or
even to vanadyl species. Therefore, strong efforts are needed to confirm
the biologically active POMs species.
4. Conclusions
The X-ray crystal structure of PV14 was solved and contains two
trans-bicapped α-Keggin anions HxPV14O42(9-x)-. The anion is built up
from the classical Keggin structure [(PO4)@(V12O36)] capped by two
[VO] units. Phosphotetradecavanadate (Cs5.6H3.4PV14O42·12H2O) syn-
thesized and characterized in this work is the best so far investigated
member of the alkali metals family of phosphotetradecavanadates,
therefore it was reasonable to employ it in the inhibition studies of P-
type ATPases. Ca2+-ATPase activity from sarcoplasmic reticulum is
inhibited by PV14 with the IC50= 5 μM. This is about ten times higher
than IC50 values reported for highly active POMs such as [α-
P2W18O62]6− (0.6 μM), but on the other hand PV14 is 3 times more
potent than V10 (15 μM) and much more potent than Nb10 (35 μM) and
[TeW6O24]6− (≈200 μM). Similarly as described before for [α-
P2W18O62]6− and [TeW6O24]6− a mixed type of inhibition was ob-
served for PV14. Therefore, a different mode of interaction with the
Ca2+-ATPase than the one observed for V10 and Nb10 (shown to be non-
competitive inhibitors) must be involved. However, PV14 was shown to
be the most potent Na+/K+-ATPase inhibitor when using an ex-vivo
model obtained from basal membrane of the skin epithelia. Thus, for
the ex-vivo Na+/K+-ATPase activity an IC50 value of 1.4 μM was ob-
served. This ex-vivo model seems to be a very specific model to study
the effects of POMs in the processes of epithelial chloride secretion
energized by basolateral Na+/K+-ATPase activity.
Abbreviations
IC50 concentration that induces 50% of Ca2+-ATPase inhibition of
the enzyme activity
ET50 the effective time (in minutes) necessary to reach 50% of the
maximum effects.






V1 vanadate, monomeric vanadate containing 1 vanadate units
V10 decavanadate, vanadate oligomer containing 10 vanadate
units
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Appendix A. Supplementary data
Supplementary data CCDC 1886317 contains the supplementary
crystallographic data for PV14. These data can be obtained free of
charge via http://www.ccdc.cam.ac.uk/conts/retrieving.html, or from
the Cambridge Crystallographic Data Centre, 12 Union Road,
Cambridge CB2 1EZ, UK; fax: +44 1223 336 033; or e-mail: deposit@
ccdc.cam.ac.uk. These data include experimental details on inhibition
studies, crystal data and structure refinement details. MOL files and
InChiKeys of the most important compounds described in this article.
Supplementary data to this article can be found online at doi:https://
doi.org/10.1016/j.jinorgbio.2019.110700.
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